Dr. Gerber is an internationally recognized leader in oncological drug discovery and development, with an exceptional track record in advancing targeted therapeutics with high success rates in the clinic. He has over 25 years of experience in oncological Research and Development, including antibody-drug conjugates (ADCs), redirected T-cell targeting compounds and adoptive T-cell therapies.

He previously led Pfizer’s Bioconjugates division as Chief Scientific Officer, overseeing Pfizer’s efforts in ADCs and redirected T-cell targeting and nanoparticle development. He also held senior leadership positions at Seattle Genetics and Genentech. Dr. Gerber is currently Chief Executive Officer and Chief Scientific Officer at 3T Biosciences, an immunotherapy company located in South San Francisco.

He has overseen 10 IND filings for ADCs (5) and CD3-bispecifics (5), with four of them currently completing phase 1 trials and two programs advancing to phase 2 testing. Dr. Gerber contributed to the preclinical pharmacology sections of four BLAs for approved oncology drugs (Avastin, Adcetris, Mylotarg, Besponsa). He is an author of over 120 peer-reviewed papers and book chapters and co-inventor of over 25 issued patents in the field of oncology drug discovery and development. He received an MS in Biochemistry and a PhD in Molecular Biology from the University of Zurich, Switzerland.